Q2 2026 delivered 6% revenue growth (9% excluding Nevro), record non-GAAP EPS, and 200 bps gross margin expansion. U.S. and international spine, trauma, and neuromonitoring drove growth, while Enabling Tech and Nevro were headwinds. Full-year EPS guidance was raised, with robust capital allocation…
Q2 2026 delivered 6% revenue growth (9% excluding Nevro), record non-GAAP EPS, and 200 bps gross margin expansion. U.S. and international spine, trauma, and neuromonitoring drove growth, while Enabling Tech and Nevro were headwinds. Full-year EPS guidance was raised, with robust capital allocation and ongoing product innovation.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
